NCT04221061TerminatedEarly phase 1
18F-FluorThanatrace (PET/CT) in Glioblastoma
A Pilot Study Evaluating in Vivo PARP-1 Expression with18F-FluorThanatrace Positron Emission Tomography (PET/CT) in Glioblastoma
Source: ClinicalTrials.gov · Last updated 17 Jun 2024
Brief summary (registry, in English)
The subject will be a candidate for this imaging study because they have agreed to participate in a treatment study involving TTFields (Optune device), a device that uses low intensity, wave like electrical fields, and a PARP inhibitor drug (niraparib). The research study is being conducted to test how a new radioactive imaging drug called 18F-Fluorthanatrace (18F-FTT) can be used to image sites of recurrent brain cancer before or after new treatment or surgery. 18F-FTT is a drug used with an imaging test called Positron Emission Tomography/Computed Tomography (PET/CT).
- Status (registry)
- Terminated
- Phase (registry)
- Early phase 1
- Study type
- Interventional
- Enrollment
- 3 (actual)
- First submitted
- 6 Jan 2020
- Start date
- 20 Feb 2020
- Primary completion date
- 10 Jun 2024
- Lead sponsor
- University of Pennsylvania
- Diseases
- Glioblastoma
- NCT number
- NCT04221061
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- Inability to tolerate imaging procedures in the opinion of an investigator or treating physician.
- Any current medical condition, illness, or disorder as assessed by medical record review and/or self-reported that is considered by a physician investigator to be a condition that could compromise participant safety or successful participation in the study
Other
- Females who are pregnant or breast-feeding at the time of screening will not be eligible for this study; a urine pregnancy test will be performed in women of childbearing potential at screening.
Who the study is looking for
- Participants will be ≥ 22 years of age
- Participants will have a diagnosis of glioblastoma and be enrolled in the companion treatment trial, IRB 832694.
- Participants must be informed of the investigational nature of this study and be willing to provide written informed consent and participate in this study in accordance with institutional and federal guidelines prior to study-specific procedures.
Age in the registry: 22 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Save your city in your profile to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| University of Pennsylvania | Philadelphia | United States | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.